Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Pituitary. 2023 Jun;26(3):269-272. doi: 10.1007/s11102-023-01308-5. Epub 2023 Mar 14.
The majority of corticotroph adenomas are benign but some are locally invasive, demonstrate high rates of recurrence, and exhibit a relatively poor response to often repeated surgical, medical, and radiation treatment. Herein, we summarize the currently known somatic and genetic mutations and other molecular factors that influence the pathogenesis of these tumors and discuss currently available therapies. Although recent molecular studies have advanced our understanding of the pathogenesis and behavior of these refractory corticotroph adenomas, these insights do not reliably guide treatment choices at present. Development of additional diagnostic tools and novel tumor-directed therapies that offer efficacious treatment choices for patients with refractory corticotroph adenomas are needed.
大多数促肾上腺皮质激素腺瘤是良性的，但有些是局部侵袭性的，复发率高，并且对经常重复的手术、药物和放射治疗反应相对较差。在此，我们总结了目前已知的影响这些肿瘤发病机制的体细胞和遗传突变以及其他分子因素，并讨论了目前可用的治疗方法。尽管最近的分子研究提高了我们对这些难治性促肾上腺皮质激素腺瘤的发病机制和行为的理解，但这些见解目前并不能可靠地指导治疗选择。需要开发额外的诊断工具和新的肿瘤靶向治疗方法，为难治性促肾上腺皮质激素腺瘤患者提供有效的治疗选择。
